The Latest Breaking News from Finch

Finch flew under the radar at launch

A new wave of wine bars is taking the capital’s coolest postcodes by storm and slaking the thirst of younger drinkers. Ben McCormack takes a sip

The U.S. Food and Drug Administration (FDA) has removed the clinical hold on Finch Therapeutics Group (NASDAQ: FNCH) investigational new drug (IND) application for CP101 in  the prevention of recurrent C. difficile infection (CDI).

Finch Therapeutics Group Inc (NASDAQ:FNCH) announced the layoff of 20% of its staff in a regulatory filing. The cuts will impact 37 full-time employees. The FDA in March placed a clinical hold on the Phase 3 trial for CP101, a donor-derived microbiome drug for Clostridioides difficile, as well as a partial hold…

The FDA has issued a clinical hold letter to Finch Therapeutics Group Inc's (NASDAQ:FNCH) PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI). The Company has paused enrollment in the trial as the FDA has asked for additional information about Finch's SARS-CoV-2 donor screening protocols. The FDA placed Finch's investigational new…

Here's a roundup of top developments in the biotech space over the last 24 hours.